Ikena Oncology, Inc. (IKNA)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Ikena Oncology, Inc. (IKNA) with AI Score 44/100 (Weak). Ikena Oncology, Inc. is a targeted oncology company focused on developing biomarker-driven medicines. Their lead product candidate, IK-930, targets the Hippo signaling pathway. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Ikena Oncology, Inc. (IKNA) Healthcare & Pipeline Overview
Ikena Oncology, Inc. is a biotechnology company specializing in targeted oncology therapies, particularly those focused on biomarker-defined patient groups. Their lead candidate, IK-930, aims to inhibit the Hippo signaling pathway, positioning them in the competitive and rapidly evolving oncology therapeutics market.
Investment Thesis
Ikena Oncology presents a notable research candidate within the biotechnology sector, driven by its targeted oncology approach and promising pipeline. The company's lead candidate, IK-930, targeting the Hippo signaling pathway, has the potential to address unmet needs in various cancers. Positive clinical trial data for IK-930 could serve as a significant catalyst, driving investor interest and potentially leading to partnerships or acquisitions. Furthermore, the development of IK-175 and IK-007 diversifies Ikena's pipeline and reduces reliance on a single asset. However, the company faces risks associated with clinical trial outcomes, regulatory approvals, and competition from other oncology therapies. With a market cap of $0.72 billion and a beta of 0.50, Ikena exhibits moderate volatility. Successful execution of its clinical programs and strategic partnerships will be crucial for realizing its long-term value.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.72 billion reflects investor valuation of Ikena Oncology's pipeline and technology.
- Beta of 0.50 indicates lower volatility compared to the broader market, potentially appealing to risk-averse investors.
- Focus on biomarker-defined patient groups aligns with the growing trend of personalized medicine in oncology.
- Development of multiple targeted therapies diversifies risk and expands potential market opportunities.
- Headquartered in Boston, a major biotechnology hub, provides access to talent, resources, and potential partnerships.
Competitors & Peers
Strengths
- Targeted oncology approach.
- Promising pipeline of drug candidates.
- Focus on biomarker-defined patient groups.
- Experienced management team.
Weaknesses
- Limited financial resources.
- Dependence on clinical trial outcomes.
- Small number of employees.
- No currently marketed products.
Catalysts
- Upcoming: Clinical trial results for IK-930 in Hippo pathway-driven cancers.
- Upcoming: Initiation of clinical trials for ERK5 inhibitor program.
- Ongoing: Advancement of IK-175 and IK-007 through clinical development.
- Ongoing: Potential for strategic partnerships and collaborations.
- Ongoing: Expansion of pipeline through internal research and development.
Risks
- Potential: Clinical trial failures for lead drug candidates.
- Potential: Regulatory delays or rejection of drug approvals.
- Potential: Competition from other oncology therapies.
- Ongoing: Dependence on securing additional funding.
- Ongoing: Intellectual property challenges and patent expirations.
Growth Opportunities
- Expansion of IK-930 into additional cancer types: IK-930, Ikena's lead candidate, targets the Hippo signaling pathway. Investigating its efficacy in other cancer types beyond the current focus could significantly expand its market potential. The Hippo pathway is implicated in various cancers, presenting opportunities for broader application. Successful clinical trials in additional indications could drive substantial revenue growth. This expansion could be pursued over the next 3-5 years.
- Advancement of ERK5 inhibitor program: Ikena's small molecule inhibitor program against ERK5 in the RAS signaling pathway represents another growth opportunity. The RAS pathway is frequently mutated in cancer, making it a valuable therapeutic target. Successful development of an ERK5 inhibitor could address a significant unmet need in RAS-driven cancers. This program is in earlier stages of development, with potential clinical trials in the next 2-3 years.
- Strategic partnerships and collaborations: Collaborating with larger pharmaceutical companies or research institutions could accelerate the development and commercialization of Ikena's pipeline. Partnerships can provide access to funding, expertise, and distribution networks. Strategic alliances could also expand Ikena's research capabilities and broaden its pipeline. These partnerships could be formed in the near term, within the next 1-2 years.
- Development of IK-175 for additional indications: IK-175, an oral inhibitor of the aryl hydrocarbon receptor (AhR), has potential applications beyond its initial target indication. Exploring its efficacy in other diseases or cancer types could expand its market opportunity. The AhR pathway is involved in various biological processes, suggesting potential for broader therapeutic use. This expansion could be pursued over the next 3-5 years.
- Commercialization of IK-007 for microsatellite stable colorectal cancer: IK-007, an oral selective EP4 receptor antagonist, is being developed for the treatment of microsatellite stable colorectal cancer. Successful commercialization of IK-007 could generate significant revenue. Colorectal cancer is a major global health burden, and new therapies are needed to improve patient outcomes. The timeline for commercialization depends on clinical trial results and regulatory approvals, potentially within the next 3-4 years.
Opportunities
- Expansion into new cancer indications.
- Strategic partnerships with larger companies.
- Advancements in personalized medicine.
- Increasing demand for targeted therapies.
Threats
- Competition from established pharmaceutical companies.
- Clinical trial failures.
- Regulatory hurdles.
- Patent expirations.
Competitive Advantages
- Proprietary targeted therapies.
- Strong intellectual property protection (patents).
- Expertise in biomarker-driven drug development.
- Focus on specific unmet needs in oncology.
About IKNA
Ikena Oncology, Inc., founded in 2016 and headquartered in Boston, Massachusetts, is a targeted oncology company dedicated to pioneering innovative medicines for patients with unmet needs. The company focuses on developing therapies that are tailored to specific biomarker-defined patient groups, aiming to improve treatment outcomes and patient lives. Ikena's lead product candidate is IK-930, an oral small molecule inhibitor targeting the transcriptional enhanced associate domain (TEAD), a transcription factor in the Hippo signaling pathway. This pathway is implicated in various cancers, making it a promising target for therapeutic intervention. Beyond IK-930, Ikena is also advancing a small molecule inhibitor program against ERK5 in the RAS signaling pathway, a critical pathway in cancer development and progression. Additionally, the company is developing IK-175, an oral inhibitor of the aryl hydrocarbon receptor (AhR), and IK-007, an oral selective EP4 receptor antagonist designed for the treatment of microsatellite stable colorectal cancer. These programs reflect Ikena's commitment to addressing a range of cancer types with targeted therapies. The company's strategy involves identifying and developing therapies that can selectively target cancer cells based on their unique molecular characteristics, with the goal of maximizing efficacy and minimizing side effects.
What They Do
- Develop targeted oncology therapies for biomarker-defined patient groups.
- Focus on unmet needs in cancer treatment.
- Develop oral small molecule inhibitors.
- Target the Hippo signaling pathway with IK-930.
- Develop inhibitors against ERK5 in the RAS signaling pathway.
- Develop IK-175, an oral inhibitor of the aryl hydrocarbon receptor (AhR).
- Develop IK-007, an oral selective EP4 receptor antagonist for colorectal cancer.
Business Model
- Develop and commercialize targeted oncology therapies.
- Out-license or partner with larger pharmaceutical companies for commercialization.
- Generate revenue through sales of approved therapies.
- Secure funding through venture capital, public offerings, and partnerships.
Industry Context
Ikena Oncology operates within the biotechnology industry, specifically focusing on oncology therapeutics. The oncology market is experiencing substantial growth, driven by an aging population, increasing cancer incidence, and advancements in targeted therapies. The competitive landscape is crowded, with numerous companies developing novel cancer treatments. Ikena's focus on biomarker-defined patient groups and targeted therapies positions it within the personalized medicine segment, which is gaining traction due to its potential for improved efficacy and reduced side effects. The company faces competition from established pharmaceutical companies and other biotechnology firms, including those developing therapies targeting similar pathways.
Key Customers
- Patients with cancer.
- Oncologists and other healthcare professionals.
- Hospitals and cancer treatment centers.
- Pharmaceutical companies (potential partners or acquirers).
Financials
Chart & Info
Ikena Oncology, Inc. (IKNA) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Lows On Thursday
benzinga · Apr 28, 2022
-
Stocks That Hit 52-Week Lows On Wednesday
benzinga · Feb 23, 2022
-
Stocks That Hit 52-Week Lows On Tuesday
benzinga · Feb 22, 2022
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IKNA.
Price Targets
Wall Street price target analysis for IKNA.
MoonshotScore
What does this score mean?
The MoonshotScore rates IKNA's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Mark Manfredi
CEO
Mark Manfredi serves as the Chief Executive Officer of Ikena Oncology, managing a team of 10 employees. His background includes extensive experience in the biotechnology and pharmaceutical industries, with a focus on oncology drug development. Prior to joining Ikena, Manfredi held leadership positions at various biotech companies, where he oversaw the development and commercialization of innovative therapies. His expertise spans drug discovery, clinical development, and business strategy. Manfredi's experience positions him to lead Ikena Oncology in its mission to develop targeted therapies for cancer patients.
Track Record: Under Mark Manfredi's leadership, Ikena Oncology has advanced its pipeline of targeted oncology therapies, including IK-930, IK-175, and IK-007. He has overseen the initiation and execution of clinical trials, as well as the expansion of the company's research and development programs. Manfredi has also been instrumental in securing funding and establishing strategic partnerships to support Ikena's growth. His leadership has been focused on driving innovation and delivering value to patients and shareholders.
What Investors Ask About Ikena Oncology, Inc. (IKNA)
What does Ikena Oncology, Inc. do?
Ikena Oncology, Inc. is a targeted oncology company focused on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. The company's lead product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain (TEAD), a transcription factor in the Hippo signaling pathway. Ikena is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway, as well as IK-175, an oral inhibitor of the aryl hydrocarbon receptor (AhR), and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company aims to improve treatment outcomes for cancer patients by developing therapies that selectively target cancer cells based on their unique molecular characteristics.
What do analysts say about IKNA stock?
Analyst coverage of Ikena Oncology (IKNA) is currently pending. Key valuation metrics to consider include the company's market capitalization of $0.72 billion and its negative price-to-earnings ratio of -1.59, reflecting its current lack of profitability. Growth considerations center on the successful development and commercialization of its pipeline of targeted oncology therapies, particularly IK-930. Investor sentiment will likely be influenced by clinical trial results and regulatory milestones. This is not investment advice, and investors should conduct their own due diligence.
What are the main risks for IKNA?
The main risks for Ikena Oncology include the potential for clinical trial failures, regulatory hurdles, and competition from other oncology therapies. The company's success depends on the successful development and commercialization of its pipeline of drug candidates, which is subject to inherent risks and uncertainties. Securing additional funding is also a critical risk, as the company currently has limited financial resources. Additionally, intellectual property challenges and patent expirations could pose a threat to Ikena's competitive position.
How does Ikena Oncology, Inc. navigate regulatory approval processes?
Ikena Oncology navigates regulatory approval processes by adhering to stringent guidelines set by regulatory agencies such as the FDA in the United States. The company's strategy includes comprehensive preclinical studies, well-designed clinical trials, and proactive communication with regulatory authorities. Ikena's regulatory track record is still developing as it advances its pipeline candidates through clinical development. The company's compliance strategy focuses on maintaining high standards of data integrity, patient safety, and ethical conduct throughout the drug development process.
How does Ikena Oncology, Inc. manage patent expiration risks?
Ikena Oncology manages patent expiration risks through a multi-faceted approach that includes actively monitoring its patent portfolio, pursuing patent extensions where possible, and developing new innovations to maintain a competitive edge. The company's patent cliff exposure is currently limited as its lead product candidates are still in early stages of development. However, Ikena's lifecycle management strategies involve exploring new formulations, indications, and combinations to extend the exclusivity of its therapies beyond the initial patent term. The company also invests in research and development to create new intellectual property and stay ahead of biosimilar competition.
What are the key factors to evaluate for IKNA?
Ikena Oncology, Inc. (IKNA) currently holds an AI score of 44/100, indicating low score. Key strength: Targeted oncology approach.. Primary risk to monitor: Potential: Clinical trial failures for lead drug candidates.. This is not financial advice.
How frequently does IKNA data refresh on this page?
IKNA prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven IKNA's recent stock price performance?
Recent price movement in Ikena Oncology, Inc. (IKNA) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Targeted oncology approach.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending may provide further insights.
- Financial data is limited and may not reflect the most current information.